ANDA 65037, held by Teva Parenteral Medicines. Idarubicin Hydrochloride.
As of Nov 22, 2026, ANDA 65037 (Idarubicin Hydrochloride), held by Teva Parenteral Medicines, was first approved by FDA on May 1, 2002, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 2002 | Original application | Approved |
| Idarubicin Hydrochloride20MG/VIAL · powder;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride10MG/VIAL · powder;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride5MG/VIAL · powder;intravenous | Idarubicin Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters